Cometriq 80mg is indicated for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have getting before anti-angiogenic therapy.
Cometriq 80mg belongs to targeted therapy drug used to cure medullary thyroid cancer and kidney cancer that has spread
Cometriq 80mg label includes a black box warning of gastrointestinal perforations, fistulas, and haemorrhage.
Cometriq 80mg is a prescription drug which is used under the supervision of doctors
Mechanism of action
Cabozantinib belongs to a type of targeted therapy drug known as tyrosine kinase inhibitor. It action by inhibiting the signals inner cancer cells which made them grow and divide. This may help to block or reduced the growth of the cancer. It can also prohibit new blood vessels growing in the cancer. Cancer cells require to make new blood vessels, so they can develop and spread.
Avoid substitute Cometriq tablets with Cabozantinib capsules.
The prescribed dose of Cometriq is 140mg (one 80mg and three 20mg).
Administration Cometriq is without food.
Advise the patients not to eat for at least 2 hours before and 1 hour after taking cometriq. Follow the treatment until patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Swallow Cometriq tablets whole. Do not crush Cometriq tablets.
• GI perforations and fistulas
• Thrombotic events
• Hypertension and hypertensive crisis
• Palmar-plantar erythrodysesthesia
• Reversible posterior leukoencephalopathy syndrome
Check the patients for symptoms of perforations and fistulas, contain abscess. stop Cometriq 80mg in patients who experience a perforation or a fistula.
Avoid administer Cometriq 80mg to patients with a present history of haemorrhage or haemoptysis.
Stop the Cometriq 80mg in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.
Stop the Cometriq 80mg for patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.
Inform pregnant women about potential risk to a foetus. Advise females of reproductive possible to use efficient contraception during treatment with Cometriq 80mg and for 4 months after the last dose